Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AVEO and Astellas Discontinue Breast Cancer Trial

Published: Friday, January 31, 2014
Last Updated: Friday, January 31, 2014
Bookmark and Share
Joint decision to discontinue trial due to insufficient enrollment.

AVEO Oncology today  announced  that AVEO and Astellas Pharma Inc.  have jointly decided to discontinue the BATON ( Biomarker Assessment of Tivozanib in ONcology ) breast  cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO  previously announced that enrollment in this study had been slower than anticipated, and enrollment rates did not improve substantially following additional patient  recruitment efforts.  

“While we believe in the potential benefits of tivozanib for patients with triple  negative breast cancer, we have decided to discontinue the trial because of low patient  accrual,” stated William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO.  “We want to thank the study investigators and their patients who participated in the  trial for their support.” 

The BATON - BC study initiated patient enrollment in December 2012 in a  randomized, double - blind, multicenter Phase 2 clinical trial, evaluating the efficacy of  tivozanib in combination with paclitaxel compared to placebo in combination with  paclitaxel in patients with locally recurrent or metastatic  triple negative breast cancer  who have received no more than one systemic therapy for advanced or metastatic  breast cancer.  All  committed expenses related to the BATON - BC study are shared  equally  between AVEO and  Astellas.  

Separately, as announced in December 2013, data from a planned interim analysis of  the Phase 2 study of tivozanib in patients with colorectal cancer indicate that the study  is unlikely to meet the primary endpoint in the intent - to - treat patient population. Interim data  are being evaluated, and  AVEO and Astellas are in discussions regarding  next steps.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AVEO Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition
Discovery of HeyL gene expression as biomarker marks critical step in developing targeted therapeutics to inhibit notch pathway.
Thursday, June 18, 2009
AVEO Initiates First Clinical Trial of Novel HGF Antagonist
AVEO initiates first clinical trial of novel HGF antagonist in patients with advanced solid tumors and lymphomas.
Wednesday, September 24, 2008
Human Tissue Transgenic Cancer Model may Offer Significant Advance Toward Modeling Human Cancer
AVEO Pharmaceuticals has created invasive human tumors that develop over time in mice from primary human breast tissue.
Thursday, April 19, 2007
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
10X Genomics Releases Linked-Read Data from NIST Genome Samples
Genome in a Bottle Consortium data submission for webinar presentation and public availability.
Study Sheds Light on the Causes of Cerebral Palsy
Wider use of genetic testing in children with CP should be considered.
Pitt Researchers to Monitor Resistance to HIV Drugs in Africa
Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa.
Environmental Epigenetics Affects Disease, Evolution
Researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism’s DNA sequence.
Critical New Insights on DNA Repair
The enzyme fumarase is key to reversing genetic damage leading to cancer and therapy resistance.
Potential Treatment for Muscular Dystrophy
A new method for producing muscle cells could offer a better model for studying muscle diseases, such as muscular dystrophy, and for testing potential treatment options.
Nanoparticles Used to Breach Mucus Barrier in Lungs
Proof-of-concept study conducted in mice is a key step toward better treatments for lung diseases.
New Biosensors for Managing Microbial ‘Workers’
Researchers at Harvard’s Wyss Institute have unveiled new biosensors that enable scientists to more effectively control and 'communicate with' engineered bacteria.
Researchers Identify Protein in Mice that Helps Prepare for Healthy Egg-sperm Union
Protein RGS2 plays a critical role in preserving the fertilizability of the ovulated egg.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!